Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | HTR1D | P28221 | 13/20 | 0.71 |
| ▸ | HTR1B | P28222 | 13/20 | 0.71 |
| ▸ | HTR1A | P08908 | 3/20 | 0.64 |
| ▸ | HTR1F | P30939 | 2/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30908918 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| Maleic Acid SCHEMBL4799792 | 0.90 | MAPT (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| Maleic Acid SCHEMBL29388300 | 0.90 | MAPT (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| Fumaric Acid SCHEMBL4799802 | 0.90 | MAPT (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL23010847 | 0.84 | HTR1D (0.72) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL5705057 | 0.84 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL8103916 | 0.83 | CYP1A2 (0.71) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL4541253 | 0.83 | HTR1D (0.71) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL4674422 | 0.83 | HTR1D (0.71) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL4673580 | 0.83 | HTR1B (0.71) | CYP1A2CYP3A4CYP2D6CYP2C9THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028499-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-02-01 | — | — | US | claimed |
| EP-3261640-A1 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of The University of California (US) | 2018-01-03 | — | — | EP | claimed |
| WO-2016138138-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-01 | — | — | WO | claimed |
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2000000487-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5852049-A | Aromatic ethers derived from indoles which are useful as medicaments | PIERRE FABRE MEDICAMENT (FR) | 1998-12-22 | — | — | US | disclosed |
| EP-0782568-A1 | AROMATIC ETHERS DERIVED FROM INDOLS SUCH AS 5HT1-LIKE LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996026936-A1 | NOVEL CYCLIC AMINO-INDOLE PIPERAZINE DERIVATIVES, PREPARATION PROCESS AND UTILIZATION AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996009288-A1 | AROMATIC ETHERS DERIVED FROM INDOLS SUCH AS 5HT1-LIKE LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | CYP1A2 427/4885CYP3A4 977/4885CYP2D6 415/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | CYP1A2 591/4885CYP3A4 2575/4885CYP2D6 1432/4885 |
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | CYP1A2 1214/4885CYP3A4 1654/4885CYP2D6 2692/4885 |
| US-20180028499-A1 | 5HT AGONISTS FOR TREATING DISORDERS | HTR1A, HTR5A, HTR2A | CYP1A2 455/4885CYP3A4 695/4885CYP2D6 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.